Special Issue

Bioethics in Personalized Medicine and Precision Medicine

Message from the Guest Editors

Personalized medicine (PM) aims to provide tailor-made prevention and treatment strategies for defined groups of individuals, with key areas including oncology, cardiology, rare diseases, infectious diseases, and pharmacogenomics. Various precision interventions are already used in health care systems around the globe and research initiatives leave promises for the rapid expansion of PM in the near-future. This growing interest has prompted considerations of several bioethical issues.

This Special Issue invites interdisciplinary contributions that explore these and other bioethical challenges emerging from personalized and precision medicine advances. We welcome discussion papers, reviews, and original research articles highlighting the ethical, legal, and social implications of recent PM advances. The aim is to foster an international dialogue among ethicists, clinicians, researchers, policymakers, and patient communities to ensure that the future of personalized and precision medicine is guided by robust ethical principles.

Guest Editors

Dr. Michael Igoumenidis

Department of Nursing, University of Patras, Patras, Greece

Dr. Venetia Sofia Velonaki

Department of Nursing, National and Kapodistrian University of Athens, 11517 Athens, Greece

Deadline for manuscript submissions

15 May 2026



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/249212

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

